AtriCure, Inc. (NASDAQ:ATRC) Receives $51.56 Consensus Target Price from Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are presently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have covered the stock in the last year is $51.56.

A number of equities analysts have recently commented on the stock. Stifel Nicolaus lifted their price target on shares of AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Piper Sandler lifted their price objective on AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Canaccord Genuity Group increased their target price on shares of AtriCure from $61.00 to $66.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on shares of AtriCure from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $51.00 price objective on shares of AtriCure in a research report on Thursday, February 13th.

Hedge Funds Weigh In On AtriCure

Several institutional investors have recently made changes to their positions in ATRC. Arcadia Investment Management Corp MI acquired a new position in AtriCure during the 3rd quarter worth approximately $28,000. Johnson Financial Group Inc. raised its position in shares of AtriCure by 1,184.1% during the fourth quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock worth $49,000 after purchasing an additional 1,492 shares during the period. Heck Capital Advisors LLC bought a new position in shares of AtriCure in the 4th quarter worth $60,000. Venturi Wealth Management LLC grew its position in AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock valued at $69,000 after purchasing an additional 2,100 shares during the period. Finally, KBC Group NV increased its stake in AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after purchasing an additional 932 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.

Remove Ads

AtriCure Trading Up 0.6 %

Shares of NASDAQ:ATRC traded up $0.23 during midday trading on Friday, hitting $38.97. 316,437 shares of the stock were exchanged, compared to its average volume of 669,238. The business's 50-day moving average price is $37.19 and its 200 day moving average price is $32.74. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -41.00 and a beta of 1.46. AtriCure has a 12 month low of $18.94 and a 12 month high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.